FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Novartis Lamisil AT Cream for Jock Itch Recall

Novartis Lamisil AT Cream for Jock Itch (terbinafine hydrochloride 1% antifungal), a)…

Novartis Consumer Health · Lincoln, NE

Risk level
Class III
Reported by FDA
Jun 12, 2013
Recall ID
D-575-2013
Check your lot numberHow we source this data

Summary

Novartis Consumer Health recalled Novartis Lamisil AT Cream for Jock Itch starting Feb 19, 2013. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-575-2013 on Jun 12, 2013. Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot. Status: Terminated.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.

Product description

Novartis Lamisil AT Cream for Jock Itch (terbinafine hydrochloride 1% antifungal), a) 12 g (.42 oz) Tube, NDC 0067-3999-12, Novartis Consumer Health, Inc., Parsitan, NJ. UPC code: 300673999121, (Vertical Pack) and b) packaged in a horizontal package12 gm (.42 oz) Tube, NDC 0067-3999-42, Novartis Consumer Health, Inc., Parsippany, NJ. UPC code: 300673999428.

Lot numbers, UPCs & expiration codes

Lot number and exp date: 10104145 30-Apr-2013. (Vertical package) and Lot number and exp date: 10109587 30-Apr-2013, 10111508 31-May-2013; 10119095 31-Jul-2013 and 10119096 30-Sep-2013 (Horizontal package).

Where it was sold

Nationwide and Puerto Rico, and Panama. Military distribution made.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-575-2013
Classification
Class III
Status
Terminated
Recall initiated
Feb 19, 2013
FDA report date
Jun 12, 2013
Quantity
219,600 tubes
Recall type
Voluntary: Firm initiated
Recalling firm
Novartis Consumer Health

Original FDA data

Every field from FDA enforcement report D-575-2013, exactly as published.

Show all FDA fields
City
Lincoln
State
NE
Status
Terminated
Country
United States
Event ID
64372
Address
10401 Hwy 6
Code information
Lot number and exp date: 10104145 30-Apr-2013. (Vertical package) and Lot number and exp date: 10109587 30-Apr-2013, 10111508 31-May-2013; 10119095 31-Jul-2013 and 10119096 30-Sep-2013 (Horizontal package).
Postal code
68517-9626
Report date
Jun 12, 2013
Product type
Drugs
Recall number
D-575-2013
Classification
Class III
Recalling firm
Novartis Consumer Health
Product quantity
219,600 tubes
Termination date
Nov 26, 2014
Reason for recall
Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Novartis Lamisil AT Cream for Jock Itch (terbinafine hydrochloride 1% antifungal), a) 12 g (.42 oz) Tube, NDC 0067-3999-12, Novartis Consumer Health, Inc., Parsitan, NJ. UPC code: 300673999121, (Vertical Pack) and b) packaged in a horizontal package12 gm (.42 oz) Tube, NDC 0067-3999-42, Novartis Consumer Health, Inc., Parsippany, NJ. UPC code: 300673999428.
Distribution pattern
Nationwide and Puerto Rico, and Panama. Military distribution made.
Recall initiation date
Feb 19, 2013
Initial firm notification
Letter
Center classification date
Jun 6, 2013

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-575-2013, published Jun 12, 2013. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls